Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial.

Trial Profile

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Avelumab (Primary)
  • Indications Breast cancer; Carcinoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms A-BRAVE
  • Most Recent Events

    • 10 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top